| Literature DB >> 31623362 |
Annunziatina Laurino1, Valentina Spinelli2, Manuela Gencarelli3, Valentina Balducci4, Leonardo Dini5, Lorenzo Diolaiuti6, Marco Ghionzoli7,8, Antonio Messineo9,10, Alessandro Mugelli11, Elisabetta Cerbai12, Laura Raimondi13, Laura Sartiani14.
Abstract
Skeletal muscle regeneration is ensured by satellite cells (SC), which upon activation undergo self-renewal and myogenesis. The correct sequence of healing events may be offset by inflammatory and/or fibrotic factors able to promote fibrosis and consequent muscle wasting. Angiotensin-II (Ang) is an effector peptide of the renin angiotensin system (RAS), of which the direct role in human SCs (hSCs) is still controversial. Based on the hypertrophic and fibrogenic effects of Ang via transient receptor potential canonical (TRPC) channels in cardiac and renal tissues, we hypothesized a similar axis in hSCs. Toward this aim, we demonstrated that hSCs respond to acute Ang stimulation, dose-dependently enhancing p-mTOR, p-AKT, p-ERK1/2 and p-P38. Additionally, sub-acute Ang conditioning increased cell size and promoted trans-differentiation into myofibroblasts. To provide a mechanistic hypothesis on TRPC channel involvement in the processes, we proved that TRPC channels mediate a basal calcium entry into hSCs that is stimulated by acute Ang and strongly amplified by sub-chronic Ang conditioning. Altogether, these findings demonstrate that Ang induces a fate shift of hSCs into myofibroblasts and provide a basis to support a benefit of RAS and TRPC channel blockade to oppose muscle fibrosis.Entities:
Keywords: Ca2+ signaling; TRPC channels; angiotensin; hypertrophy; myofibroblast; myogenesis; satellite cells; skeletal muscle
Mesh:
Substances:
Year: 2019 PMID: 31623362 PMCID: PMC6801484 DOI: 10.3390/ijms20194912
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Phenotype of cultured human satellite cells (hSCs): immunolabelling (a) and percentage of positive cells (b) for Paired box protein 7 (PAX7), myogenic factor 5 (MYF5), myogenic factor 3 (MYOD), myogenin, and myosin heavy chain (MHC) in cultured hSCs at passage 3. Target proteins are depicted in red, and cell nuclei are in blue (DAPI). The image magnification is 20×.
Figure 2Expression of renin angiotensin system (RAS) proteins in activated hSCs: (a) immunolabelling of type-1 (AT1), type-2 (AT2), and MAS receptors, and angiotensin-converting enzymes 1 (ACE1) and 2 (ACE2) in cultured hSCs at passage 3. Target proteins are depicted in red, cell nuclei are in blue (DAPI). The image magnification is 20×; (b) immunoblotting (top) and densitometric analysis (bottom) of AT1, AT2, and MAS receptors, and ACE1 and ACE2 in protein extracts of hSCs at passage 3. The histogram shows the ratios (mean ± standard error of the mean (SEM), n = 3) between the expression levels of target proteins and GAPDH.
Figure 3Signaling cascade stimulated by acute Ang in hSCs: (a) representative immunoblotting of p-mTOR, p-AKT, p-ERK1/2, p-P38, and GADPH detected in protein extracts of cultured hSCs stimulated or not (CTR) with 1–100 nM angiotensin II (Ang) for 15 min with/without 1 µM irbesartan (Irb); densitometric analysis of p-mTOR (b), p-AKT (c), p-ERK1/2 (d), and p-P38 (e) levels, reported as ratios between the levels of the target protein and GAPDH. Results are presented as mean ± SEM of the three gels. * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR.
Figure 4Effect of sub-chronic conditioning with Ang on hSC-size and myofibroblast markers: (a) Representative photomicrographs of cells labelled with Alexa Fluor (red) and DAPI (blue); (b) Values of cell cross-sectional areas (mean ± SEM) evaluated blind by two researchers using the drawing function of ImageJ software; immunolabelling and relative quantifications of α-smooth muscle actin (c,d), transgelin-2 (e,f), and β-catenin (g,h). Target proteins are stained in red, cell nuclei are in blue (DAPI). Quantifications of protein expression were performed blind by two researchers. All image magnifications are 20×; (i) immunoblotting (top) of myostatin detected in protein extracts of cultured hSCs and densitometric quantification (bottom). * p < 0.05, ** p < 0.01 and *** p < 0.001. In this experiment, hSCs were cultured for 24 h in a standard medium (M) or M supplemented with 100 nM Ang (M + Ang), or 1 µM irbesartan (M + Irb) or 1 µM Irb plus 100 nM Ang (M + Irb + Ang).
Figure 5Functional coupling between Ang and TRPC channels on hSCs: (a) mRNA expression of TRPC1–7 channels in hSCs at passage 3; (b) immunolabelling of TRPC1, 3, 4, 6 channels in hSCs. Channel proteins are stained in red, and nuclei are in blue (DAPI). All image magnifications are 20X; (c) experimental scheme (top) used for 24 h conditioning of hSCs prior to fluorescence calcium imaging. Culture conditions were: M supplemented with 100 nM Ang (M + Ang), 100 nM Ang plus 1µM irbesartan (M + Ang + Irb), or 100 nM Ang plus 100 nM PD123319 (M + Ang + PD). The experimental protocol to perform fluorescence calcium imaging used a vehicle solution (Veh) supplemented with 5 µM cyclopentyladenosine (Veh + CPA) and 0 or 1.8 mM CaCl2 to stimulate a transient intracellular Ca2+ entry (trace c1). The histogram (bottom) shows mean peak values (±standard error) of Ca2+ transients measured in cells cultured in the M for 24 h (column d1), exposed to acute 5 µM SKF (d2, trace c2,), 100 nM Ang (d3, trace c3,), Ang plus SKF (d4, trace c4), Ang plus Irb (d5, trace c5), and Ang plus PD (d6, trace c6). Ca2+ transients measured in cells conditioned for 24 h in M + Ang (top scheme) are represented by trace c7 and column d7, and by trace c8 and column d8 after acute stimulation by 100 nM Ang. Similar measurements were performed in: cells conditioned for 24 h in M + Ang + Irb (top scheme) without/with acute stimulation by Ang (trace c9, column d9/trace c10, column d10); cells conditioned for 24 h in M + Ang + PD (top scheme) without/with acute stimulation by Ang (trace c11, column d11/trace c12, column d12). * p < 0.05, *** p < 0.001.
Figure 6Effect of sub-chronic Ang conditioning of hSCs on expression of AT1 and AT2 receptors: (a) Representative immunoblotting (top) and densitometry analysis (bottom) of AT1 receptors expressed in hSCs cultured for 24 h in the M supplemented or not with 100 nM Ang, 1 µM Irb, or Ang plus Irb (Ang + Irb); (b) representative immunoblotting (top) and densitometry analysis (bottom) of AT2 receptors expressed in hSCs cultured as in (a). Densitometry analysis is reported as ratios between the levels of the target protein and GAPDH. Results are presented as mean ± SEM of the three gels. * p < 0.05 vs. M, ** p < 0.01 vs. M.
List of primary and secondary antibodies used for immunofluorescence (IF) and western blot (WB) analysis.
| Antibodies | Dilution | Supplier |
|---|---|---|
| Anti-ACE1 | 1:50 (IF) | Santa Cruz Biotechnology, Heidelberg, Germany |
| Anti-ACE2 | 1:50 (IF) | Santa Cruz Biotechnology, Heidelberg, Germany |
| Anti-ATR1 | 1:100 (IF) | Alomon Labs, Jerusalem, Israel |
| Anti-ATR2 | 1:200 (WB) | Alomon Labs, Jerusalem, Israel |
| Anti-GAPDH | 1:7000 (WB) | Merk-Millipore, Darmstadt, Germany |
| Anti-Myf5 | 1:100 (IF) | Santa Cruz Biotechnology, Heidelberg, Germany |
| Anti-MyoD | 1: 100 (IF) | Santa Cruz Biotechnology, Heidelberg, Germany |
| Anti-myogenin | 1:100 (IF) | Developmental Studies Hybridoma Bank, Iowa City, Iowa, United States of America |
| Anti-myostatin | 1:300 (WB) | Biorbyt Explore, Cambridge, United Kingdom |
| Anti-myosin heavy chain | 1:100 (IF) | BD Pharmingen, San Jose, California, United States of America |
| Anti-Pax7 | 1:100 (IF) | Developmental Studies Hybridoma Bank, Iowa City, Iowa, United States of America |
| Anti-p-AKT | 1:1000 (WB) | Cell Signaling Technology, Leiden, The Netherlands |
| Anti-p-ERK1/2 (Thr202/Tyr204) | 1:1000 (WB) | Cell Signaling Technology, Leiden, The Netherlands |
| Anti-p-mTOR | 1:1000 (WB) | Cell Signaling Technology, Leiden, The Netherlands |
| Anti-p-P38 | 1: 400 (WB) | Cell Signaling Technology, Leiden, The Netherlands |
| Anti-TRPC1 | 1:100 (IF) | Alomon Labs, Jerusalem, Israel |
| Anti-TRPC3 | 1:100 (IF) | Alomon Labs, Jerusalem, Israel |
| Anti-TRPC4 | 1:100 (IF) | Alomon Labs, Jerusalem, Israel |
| Anti-TRPC5 | 1:100 (IF) | Alomon Labs, Jerusalem, Israel |
| Anti-TRPC7 | 1:100 (IF) | Alomon Labs, Jerusalem, Israel |
| Anti-Mas receptor | 1:100 (IF) | Santa Cruz Biotech, Heidelberg, Germany |
| Anti-smooth muscle actin | 1:100 (IF) | Dako, Santa Clara, California, United States of America |
| Anti-catenin | 1:1000 (IF) | BD Pharmingen, San Jose, California, United States of America |
| Anti-transgelin 2 | 1:100 (IF) | Everest Biotech, Upper Heyford, United Kingdom |
| Anti-vimentin | 1:100 (IF) | Santa Cruz Biotech, Heidelberg, Germany |
| Anti-rabbit IgG-Alexa Fluor 594 | 1:500 (IF) | Thermo Fisher scientific, Bengaluru, India |
| Anti-chicken IgG-Alexa Fluor 647 | 1:500 (IF) | Thermo Fisher scientific, Bengaluru, India |